LIXTE Biotechnology (LIXT) announced that its Board of Directors has approved a strategic capital allocation initiative to acquire cryptocurrency as part of its corporate treasury. The Board approved allocation of up to 25% of its treasury to cryptocurrencies, including Bitcoin and potentially other digital assets as it deems appropriate. The Company intends to hold all cryptocurrency assets with a fully regulated and compliant custodian. All future transactions will adhere strictly to applicable financial, legal and audit regulations to ensure transparency, security and full regulatory compliance.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LIXT:
- Lixte Biotechnology Regains Nasdaq Compliance After Fundraising
- Lixte regains compliance with Nasdaq’s Continued Listing requirements
- Lixte’s LB100 Clinical Trials Validated by Nature
- Lixte Biotechnology announces publication in Nature journal on LB100 trials
- Lixte Biotechnology Closes $1.5M Direct Offering